Clinician Attitudes and Behaviors Regarding Use of Pre-Exposure Prophylaxis (PrEP) for Primary HIV Prevention

University of North Carolina (UNC)

Status: Completed

Conditions: Clinician Attitudes About PrEP

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT01751659

ATN 111

Details and patient eligibility

About

This is a three phase study designed to examine clinician behaviors with regard to recommending and prescribing pre-exposure prophylaxis (PrEP) as a primary Human Immunodeficiency Virus (HIV) prevention strategy, and to identify knowledge-related and attitudinal factors associated with these behaviors. Each phase consists of the following:

Phase 1: Semi-structured face-to-face or telephone interviews of ATN-affiliated clinicians. Approximately 10 clinicians will be interviewed.

Phase 2: Development of a new theory-based survey instrument and cognitive interview testing of this survey. Approximately five clinicians (of those who participated in Phase 1) will be interviewed.

Phase 3: Administration of the newly developed survey to ATN-affiliated clinicians. Approximately 60 clinicians will be interviewed.

Enrollment: 62 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Clinicians (including physicians, nurse practitioners, and physician assistants) that EITHER: Provide primary HIV care for HIV-infected and primary care for HIV-uninfected adolescents; OR Provide primary HIV care to HIV-infected adolescents only;
• Provides services to adolescents and young adults at ATN sites or one of their community partners;
• Ability to understand spoken English; and
• For Phase 2 only: prior participation in Phase 1.

Exclusion criteria

• Intoxicated or under the influence of alcohol or other substances at the time of consent;
• Visibly distraught and/or visibly emotionally unstable (i.e., exhibiting suicidal, homicidal, or violent behavior) and in the opinion of the protocol chair would interfere with the ability to give true informed consent; and
• For Phase 3 only: prior participation in Phase 1 or 2 of this study.

Trial design

62 participants in 3 patient groups

Phase I

Description:

* Semi-structured face-to-face or telephone interviews of 10 ATN-affiliated clinicians. * The total duration of Phase 1 is expected to last approximately nine months, including data analysis.

Phase II

Description:

* Development of a new theory-based survey instrument and cognitive interview testing of this survey with approximately five clinicians (of those who participated in Phase 1). * The total duration of Phase 2 is expected to last approximately three months, including qualitative analysis of the interviews and modification of the survey.

Phase III

Description:

* Administration of the newly developed survey to approximately 60 ATN-affiliated clinicians. * The total duration of Phase 3 will last approximately six to nine months.